HTGF et al. back InnoCyte

The financing will push growth and further advance the company's technology, Split.It, before it enters the market in the summer of 2013.

Company
InnoCyte has developed a laboratory desktop device called Split.It that simplifies the production of biological cells, focusing on the central routine process of "passage".

The company is a spin-off from the Fraunhofer Institute for Production Technology and Automation IPA and was already supported financially by Fraunhofer at its foundation in the summer of 2011.

Over the next few years Split.It plans to add various further devices focused on automated cell cultures, resulting in a complete family of products.

People
Fraunhofer's Matthias Keckl, HTGF investment manager Matthias Dill and MBG investment manager Florentin Walker worked on the deal.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• High-Tech Gründerfonds
• Germany